Morgan Stanley Exits Position in Apellis Pharmaceuticals, Inc. (APLS)

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G/A with the SEC, indicating that they have fully exited their position in Apellis Pharmaceuticals, Inc. (APLS). As of the event date of May 31, 2026, the filers reported owning 0 shares of common stock, representing a 0.0% ownership stake. This amendment confirms that the reporting persons have ceased to be beneficial owners of more than five percent of the company's class of securities. The filing was made under Rule 13d-1(b), certifying that the securities were originally held in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. The joint filing highlights that Morgan Stanley Capital Services LLC previously held a significant portion of the interest but now also reports zero shares. This complete exit marks a significant change from previous filings where the entities held a reportable position in the Waltham, Massachusetts-based pharmaceutical company.